RU2008105481A - Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств - Google Patents
Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств Download PDFInfo
- Publication number
- RU2008105481A RU2008105481A RU2008105481/15A RU2008105481A RU2008105481A RU 2008105481 A RU2008105481 A RU 2008105481A RU 2008105481/15 A RU2008105481/15 A RU 2008105481/15A RU 2008105481 A RU2008105481 A RU 2008105481A RU 2008105481 A RU2008105481 A RU 2008105481A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- prevention
- renal
- guanilatic
- cylin
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 239000012190 activator Substances 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 239000000021 stimulant Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 8
- 206010038464 renal hypertension Diseases 0.000 claims abstract 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 4
- 150000004677 hydrates Chemical class 0.000 claims abstract 4
- 201000006370 kidney failure Diseases 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract 2
- 208000033626 Renal failure acute Diseases 0.000 claims abstract 2
- 201000011040 acute kidney failure Diseases 0.000 claims abstract 2
- 208000012998 acute renal failure Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000000069 prophylactic effect Effects 0.000 claims abstract 2
- 238000011084 recovery Methods 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Применение соединений формул (I) - (VI) ! ! ! и их солей, гидратов, гидратов солей и сольватов для производства лекарственного средства для профилактики и/или лечения почечной недостаточности или почечной гипертонии. ! 2. Применение по п.1 для производства лекарственного средства, улучшающего восстановление от острой почечной недостаточности или почечной гипертонии. ! 3. Применение по п.1 или 2, где лекарственное средство предназначено для перорального применения. ! 4. Применение по п.1 или 2, где лекарственное средство предназначено для профилактического применения. ! 5. Фармацевтическая композиция для лечения почечной недостаточности или почечной гипертонии, включающая эффективное количество, по меньшей мере, одного соединения формул (I) - (VI), определенных в п.1.
Claims (5)
1. Применение соединений формул (I) - (VI)
и их солей, гидратов, гидратов солей и сольватов для производства лекарственного средства для профилактики и/или лечения почечной недостаточности или почечной гипертонии.
2. Применение по п.1 для производства лекарственного средства, улучшающего восстановление от острой почечной недостаточности или почечной гипертонии.
3. Применение по п.1 или 2, где лекарственное средство предназначено для перорального применения.
4. Применение по п.1 или 2, где лекарственное средство предназначено для профилактического применения.
5. Фармацевтическая композиция для лечения почечной недостаточности или почечной гипертонии, включающая эффективное количество, по меньшей мере, одного соединения формул (I) - (VI), определенных в п.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05015522.5 | 2005-07-18 | ||
| EP05015522 | 2005-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008105481A true RU2008105481A (ru) | 2009-08-27 |
Family
ID=37075729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008105481/15A RU2008105481A (ru) | 2005-07-18 | 2006-07-06 | Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100016305A1 (ru) |
| EP (1) | EP1906957A1 (ru) |
| JP (1) | JP2009501739A (ru) |
| KR (1) | KR20080030669A (ru) |
| CN (1) | CN101222923A (ru) |
| AU (1) | AU2006272088A1 (ru) |
| BR (1) | BRPI0614001A2 (ru) |
| CA (1) | CA2615426A1 (ru) |
| IL (1) | IL188657A0 (ru) |
| MX (1) | MX2008000779A (ru) |
| RU (1) | RU2008105481A (ru) |
| WO (1) | WO2007009607A1 (ru) |
| ZA (1) | ZA200800466B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007015034A1 (de) * | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9260424B2 (en) | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| ES2549979T3 (es) * | 2010-05-26 | 2015-11-03 | Adverio Pharma Gmbh | El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS) |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| KR20140019004A (ko) | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 시클라제 활성화제 |
| EP2585055A1 (de) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| DK2892891T3 (da) | 2012-09-07 | 2019-10-14 | Boehringer Ingelheim Int | Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer |
| EP3827863B1 (en) * | 2013-03-14 | 2023-06-07 | Fisher & Paykel Healthcare Limited | Catheter mount with suction port |
| JP6694385B2 (ja) * | 2013-08-09 | 2020-05-13 | アーデリクス，インコーポレーテッド | リン酸塩輸送阻害のための化合物及び方法 |
| CN106132342B (zh) * | 2014-03-17 | 2019-09-13 | 直观外科手术操作公司 | 将远程操作外科手术器械固定到致动器的闩锁 |
| EA032972B1 (ru) | 2014-07-22 | 2019-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы |
| CN104434845B (zh) * | 2014-11-12 | 2017-12-05 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002851A1 (en) * | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
| DE102004012365A1 (de) * | 2004-03-13 | 2005-09-29 | Bayer Healthcare Ag | Substituierte Dihydropyridine |
-
2006
- 2006-07-06 EP EP06762455A patent/EP1906957A1/en not_active Withdrawn
- 2006-07-06 RU RU2008105481/15A patent/RU2008105481A/ru not_active Application Discontinuation
- 2006-07-06 AU AU2006272088A patent/AU2006272088A1/en not_active Abandoned
- 2006-07-06 JP JP2008521837A patent/JP2009501739A/ja active Pending
- 2006-07-06 WO PCT/EP2006/006601 patent/WO2007009607A1/en not_active Ceased
- 2006-07-06 BR BRPI0614001-7A patent/BRPI0614001A2/pt not_active IP Right Cessation
- 2006-07-06 US US11/989,068 patent/US20100016305A1/en not_active Abandoned
- 2006-07-06 MX MX2008000779A patent/MX2008000779A/es unknown
- 2006-07-06 KR KR1020087003678A patent/KR20080030669A/ko not_active Withdrawn
- 2006-07-06 CA CA002615426A patent/CA2615426A1/en not_active Abandoned
- 2006-07-06 CN CNA2006800260905A patent/CN101222923A/zh active Pending
-
2008
- 2008-01-08 IL IL188657A patent/IL188657A0/en unknown
- 2008-01-16 ZA ZA200800466A patent/ZA200800466B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100016305A1 (en) | 2010-01-21 |
| WO2007009607A1 (en) | 2007-01-25 |
| MX2008000779A (es) | 2008-02-21 |
| CA2615426A1 (en) | 2007-01-25 |
| BRPI0614001A2 (pt) | 2011-03-01 |
| IL188657A0 (en) | 2008-12-29 |
| CN101222923A (zh) | 2008-07-16 |
| KR20080030669A (ko) | 2008-04-04 |
| AU2006272088A1 (en) | 2007-01-25 |
| EP1906957A1 (en) | 2008-04-09 |
| JP2009501739A (ja) | 2009-01-22 |
| ZA200800466B (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008105481A (ru) | Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств | |
| RU2384580C2 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| AP1635A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease. | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| NO20051259L (no) | Biaryl-diazabicykloalkanamider som nikotinacetylcholinagonister | |
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| RU2008142261A (ru) | Фармацевтическая композиция с модифицированным высвобождением и ее применение | |
| BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
| MA29619B1 (fr) | Derive de 1,1 -dioxyde de 1,4-benzothiazepine, procede de preparation, medicaments comprenant ce compose, et utilisation de celui-ci comme hypolipidemiant | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| EA200601802A1 (ru) | Производные морфолина | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| CL2004001050A1 (es) | Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
| DE60121804D1 (de) | Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin | |
| DK1735296T3 (da) | Materialer og fremgangsmåder til behandling af koagulationslidelser | |
| ATE308540T1 (de) | Antithrombosemittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20111114 |